SiBone (NASDAQ:SIBN) Receives "Sell (D-)" Rating from Weiss Ratings

Key Points

• SiBone has received a "sell (D-)" rating from Weiss Ratings, as analysts continue to express concern over the stock's performance.
• The company is currently rated as a "Moderate Buy" with an average price target of $23.67, despite mixed opinions from various analysts.
• SiBone's stock is currently trading at $15.21, with a market cap of $656.16 million and a reported EPS of ($0.14) for the most recent quarter.

SiBone (NASDAQ:SIBN - Get Free Report)'s stock had its "sell (d-)" rating reiterated by analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

A number of other analysts also recently issued reports on the stock. Cantor Fitzgerald set a $25.00 price target on shares of SiBone and gave the stock an "overweight" rating in a report on Monday, August 11th. Wall Street Zen downgraded shares of SiBone from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $23.67.

SiBone Stock Down 0.8%

SIBN stock opened at $15.21 on Wednesday. The company has a market cap of $656.16 million, a price-to-earnings ratio of -27.16 and a beta of 0.83. The company has a current ratio of 8.38, a quick ratio of 7.00 and a debt-to-equity ratio of 0.21. SiBone has a 12 month low of $11.70 and a 12 month high of $20.05. The firm has a 50-day moving average of $15.60 and a two-hundred day moving average of $16.26.

SiBone (NASDAQ:SIBN - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.05. The company had revenue of $48.63 million during the quarter, compared to the consensus estimate of $48.12 million. SiBone had a negative net margin of 12.83% and a negative return on equity of 14.20%. SiBone has set its FY 2025 guidance at EPS. As a group, analysts forecast that SiBone will post -0.78 earnings per share for the current fiscal year.

Insider Activity

In related news, SVP Michael A. Pisetsky sold 3,329 shares of the stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $15.64, for a total transaction of $52,065.56. Following the completion of the transaction, the senior vice president owned 258,352 shares of the company's stock, valued at approximately $4,040,625.28. This trade represents a 1.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Laura Francis sold 11,343 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $15.60, for a total transaction of $176,950.80. Following the transaction, the chief executive officer directly owned 419,704 shares of the company's stock, valued at $6,547,382.40. The trade was a 2.63% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 44,141 shares of company stock worth $680,628 in the last three months. 4.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On SiBone

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. ANTIPODES PARTNERS Ltd purchased a new position in SiBone in the 1st quarter valued at approximately $34,000. State of Wyoming purchased a new position in SiBone in the 2nd quarter valued at approximately $55,000. Canada Pension Plan Investment Board purchased a new position in SiBone in the 2nd quarter valued at approximately $68,000. GAMMA Investing LLC boosted its position in SiBone by 20,352.6% in the 1st quarter. GAMMA Investing LLC now owns 3,886 shares of the company's stock valued at $55,000 after buying an additional 3,867 shares during the period. Finally, Virtus Advisers LLC purchased a new position in SiBone in the 1st quarter valued at approximately $58,000. Hedge funds and other institutional investors own 98.11% of the company's stock.

SiBone Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.